Company news

Mirum Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics

July 16, 2023

Mirum Pharmaceuticals Showcases Five New LIVMARLI (maralixibat) Presentations at the EASL Congress

June 22, 2023

Event-Free Survival Data from Mirum’s LIVMARLI Alagille Syndrome Program Published in Hepatology

June 13, 2023

Mirum Pharmaceuticals to Present New LIVMARLI Data at the 2023 EASL Congress

June 6, 2023

Data from Mirum’s LIVMARLI Studies Presented at ESPGHAN Annual Meeting

May 18, 2023

Hepatology Communications Publishes Data from Mirum’s LIVMARLI in Primary Sclerosing Cholangitis

May 17, 2023

Mirum Pharmaceuticals to Showcase LIVMARLI Data at ESPGHAN Annual Meeting

May 16, 2023

Mirum Pharmaceuticals Announces Enrollment Completion in Phase 2b EMBARK Biliary Atresia Study

May 10, 2023

Mirum Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

May 3, 2023

Mirum Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023

April 26, 2023

Mirum Pharmaceuticals Prices Upsized $275.0 Million Convertible Senior Notes Offering

April 12, 2023

Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering

April 11, 2023

Mirum Pharmaceuticals Announces Preliminary Unaudited First Quarter 2023 Financial Results

April 11, 2023

Industry Leader Tim Walbert Joins Mirum Pharmaceuticals’ Board of Directors

April 5, 2023

Mirum Submits for European Approval of LIVMARLI in Progressive Familial Intrahepatic Cholestasis

April 4, 2023

Mirum Announces Label Expansion for LIVMARLI in the United States to Include Infants Three Months of Age and Older

March 13, 2023

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update

March 7, 2023

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2022 Financial Results and Host Conference Call on March 8, 2023

February 28, 2023

Mirum Pharmaceuticals Submits Supplemental New Drug Application to FDA for LIVMARLI in Patients with Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis

February 13, 2023

Mirum Pharmaceuticals to Participate in SVB Securities Global Biopharma Conference

February 8, 2023

Mirum Pharmaceuticals Announces Preliminary Unaudited LIVMARLI 2022 Net Revenue and Provides Corporate Updates

January 8, 2023

Mirum Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023

January 2, 2023

Mirum Pharmaceuticals Appoints Lon Cardon to Board of Directors

December 18, 2022

Mirum Pharmaceuticals’ LIVMARLI (maralixibat) Approved by the European Commission for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome Two Months and Older

December 12, 2022

Mirum Pharmaceuticals Provides Development Program Updates

November 28, 2022

Mirum Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

November 8, 2022

Mirum Presents New Data from LIVMARLI Phase 3 PFIC Study and ALGS Infant Study in Late-Breaker Presentations at The Liver Meeting of AASLD

November 6, 2022

Mirum Pharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 9, 2022

October 31, 2022

Mirum’s LIVMARLI Data Featured in Two Late-Breaker Presentations at The Liver Meeting of the American Association for the Study of Liver Diseases

October 30, 2022

Positive Topline Data Announced from Mirum’s LIVMARLI Phase 3 MARCH Study in Progressive Familial Intrahepatic Cholestasis (PFIC)

October 23, 2022

Mirum Pharmaceuticals’ LIVMARLI Data Highlighting Quality of Life and Sleep Improvements in Patients with Alagille Syndrome Published in Journal of Pediatrics

October 17, 2022

Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for Cholestatic Pruritus in Patients with Alagille Syndrome Two Months of Age and Older

October 13, 2022

Mirum Pharmaceuticals Presents Long-Term LIVMARLI® (maralixibat) Data and New Alagille Syndrome Caregiver Burden Analysis at NASPGHAN 2022 Annual Meeting

October 11, 2022

Mirum Pharmaceuticals to Present LIVMARLI® (maralixibat) Analyses and Host a Scientific Symposium at NASPGHAN 2022 Annual Meeting

October 4, 2022

Mirum Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock

August 11, 2022

Mirum Pharmaceuticals Announces Pricing of Public Offering of Common Stock

August 8, 2022

Mirum Pharmaceuticals Announces Commencement of Public Offering of Common Stock

August 8, 2022

Mirum Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

August 3, 2022

Mirum Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on August 4, 2022

July 27, 2022

Mirum Pharmaceuticals Presents New Data at The International Liver Congress™ of the European Association for the Study of the Liver (EASL)

June 23, 2022

Mirum Pharmaceuticals Highlights Data Demonstrating Impact of LIVMARLI® (maralixibat) on Patients with Alagille Syndrome at European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Annual Meeting

June 23, 2022

Mirum Pharmaceuticals to Showcase LIVMARLI® (maralixibat) Data at EASL and ESPGHAN Annual Congresses

June 12, 2022

Mirum Pharmaceuticals Appoints Saira Ramasastry to Board of Directors

June 5, 2022

Mirum Pharmaceuticals Acquires Satiogen Pharmaceuticals

May 22, 2022

Mirum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

May 4, 2022

Mirum Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on May 5, 2022

May 1, 2022

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update

March 8, 2022

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End Business Results for 2021 and Host Conference Call on March 9, 2022

March 1, 2022

Mirum Pharmaceuticals to Present at SVB Leerink 11th Annual Global Healthcare Conference

February 8, 2022

Mirum Pharmaceuticals Provides Business Update and Highlights Key 2022 Corporate Milestones

January 10, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 20 calls. Every call is listed under its year.

Decks

The 5 newest of 22 decks. Every deck is listed under its year.